In patients on TNF-α-blocking therapy fifty-six instances of dermatological conditions were recorded in 34 patients (47%) and included, among others, 10 drug reactions – while the patient was receiving gold (7), nonsteroidal anti-inflammatory drugs (2), or methotrexate (1) – 10 cases of eczema, 9 of mycosis, 3 of other infections, and 5 of chronic venous insufficiency. Here, TNF is linked to chronic venous insufficiency.